Deprescribing: a Portrait and Out-comes of the Reduction of Polypharmacy in Portugal (DePil17-20)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03283735 |
Recruitment Status : Unknown
Verified February 2018 by Pedro Augusto Simões, University of Beira Interior.
Recruitment status was: Not yet recruiting
First Posted : September 14, 2017
Last Update Posted : February 19, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Polypharmacy Deprescriptions | Behavioral: Elderly Enablement | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 380 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | This phase of the study is expected to start in September 2019 and will last for 6 months. Two groups will be created with a minimum of 190 patients each, one of which will be composed from patients from the region of Aveiro, Coimbra and Guarda and the other from patients from the region of Castelo Branco, Leiria and Viseu. In the intervention group the investigators will give enablement tools and talks with their GPs about how to issue the problem of polypharmacy. The information given in this group will result from the knowledge obtained in phase II in the shape of small leaflets and other information materials to be made according to the best practice, to be given and remembered at scheduled times to the intervention group. |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Prevention |
Official Title: | Deprescribing: a Portrait and Out-comes of the Reduction of Polypharmacy in Portugal |
Estimated Study Start Date : | September 1, 2019 |
Estimated Primary Completion Date : | April 1, 2020 |
Estimated Study Completion Date : | April 1, 2020 |
Arm | Intervention/treatment |
---|---|
Experimental: Elderly Enablement
The investigators will give enablement tools and talks with their GPs about how to issue the problem of polypharmacy.
|
Behavioral: Elderly Enablement
The information given in this group will result from the knowledge obtained in previous phase of the study in the shape of small leaflets and other information materials to be made according to the best practice, to be given and remembered at scheduled times to the intervention group |
No Intervention: Control
This will be the control group.
|
- Willingness to be deprescribed after the intervention with open-questions [ Time Frame: six months ]Assess the enablement of older adults while being Deprescribed in the rise of Willingness to be Deprescribed with two open-questions (one to assess the facilitators and the other to assess the barriers) together with their perception of medication (Beliefs about Medicines Questionnaire).
- Quality of life after the intervention with EQ-5D [ Time Frame: six months ]Assess the enablement of older adults while being Deprescribed in the rise of their Quality wtih EuroQol Five Dimensions Questionnaire (EQ-5D)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 65 Years and older (Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Patients attending to the primary care consultation in the selected health centres.
Exclusion Criteria:
- Being acutely unwell in the last three weeks
- Refuse to participate

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03283735
Contact: Pedro Augusto Simões, Master | +351968384396 | pedro.augusto.simoes@ubi.pt |
Principal Investigator: | Pedro Augusto Simões, Master | University of Beira Interior |
Documents provided by Pedro Augusto Simões, University of Beira Interior:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Pedro Augusto Simões, Doctor, University of Beira Interior |
ClinicalTrials.gov Identifier: | NCT03283735 |
Other Study ID Numbers: |
UBIMED2017 |
First Posted: | September 14, 2017 Key Record Dates |
Last Update Posted: | February 19, 2018 |
Last Verified: | February 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Deprescribing Polypharmacy Elderly Enablement Quality of Life |